Why the study?
Does dexrazoxane reduce cardiotoxicity in patients with advanced breast cancer receiving doxorubicin-containing therapy?
Does dexrazoxane reduce cardiotoxicity in patients with advanced breast cancer receiving doxorubicin-containing therapy?
Dexrazoxane is the first agent shown to significantly reduce doxorubicin-induced cardiotoxicity in patients with advanced breast cancer.
Supports dexrazoxane for cardioprotection with doxorubicin in advanced breast cancer; extends evidence without compromising progression or survival.
DZR had a significant cardioprotective effect as measured by noninvasive testing and clinical CHF. One of the two studies (088001) showed a lower response rate with DZR, but time to progression and survival were not significantly different. DZR is the first agent shown to reduce cardiotoxicity from doxorubicin.
No takes yet. Share an insight, caveat, or question.
Swain et al. (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: